Wegovy for Alcohol Use Disorder: Evidence, Risks, and What Patients Need to Know

What Is the FDA-Approved Use of Wegovy, and Why Is AUD Different?

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a body mass index of 30 or above, or 27 or above in the presence of at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The FDA label also covers reduction of major adverse cardiovascular events following the SELECT trial results in 2023. Alcohol use disorder is not listed anywhere in that approval.

Off-label prescribing is legal in the United States. Physicians may prescribe any approved drug for an unapproved indication when clinical judgment supports it. The critical distinction is that an off-label use carries no FDA-validated efficacy or safety data specific to that indication, which shifts more of the risk-benefit calculation onto the prescribing clinician and the informed patient.

Why the AUD Interest Emerged

The curiosity about semaglutide and alcohol did not come from nowhere. Alcohol use disorder affects roughly 29.5 million Americans aged 12 and older, according to the 2022 National Survey on Drug Use and Health via SAMHSA. Only three medications carry FDA approval for AUD: naltrexone (oral and injectable), acamprosate, and disulfiram. Fewer than 10% of people with AUD ever receive pharmacotherapy, leaving a massive treatment gap. Researchers began noticing anecdotal reports of patients on GLP-1 receptor agonists spontaneously reducing alcohol consumption, which accelerated formal investigation.

How GLP-1 Receptors Connect to Reward

GLP-1 receptors are expressed not only in the pancreas and gut but also in the ventral tegmental area, nucleus accumbens, and prefrontal cortex, the core nodes of the brain's reward circuitry. Preclinical work published in Addiction Biology showed that GLP-1 receptor activation in rodents blunts dopamine release triggered by alcohol, reducing voluntary ethanol intake. That neurobiological overlap is why researchers moved from weight-loss observations to formal addiction trials.

What Does the Human Evidence Actually Show?

The honest answer: encouraging but not definitive. No phase 3 randomized controlled trial using semaglutide 2.4 mg has reported results specifically in AUD patients as of mid-2025. The existing human data come from smaller trials, cohort analyses, and secondary endpoints in obesity studies.

The ARCS Trial

The most cited human study is the Alcohol Reduction with Subcutaneous Semaglutide (ARCS) trial, a randomized, double-blind, placebo-controlled study of 127 adults with AUD and overweight or obesity. Participants received semaglutide titrated to 1.0 mg weekly over 8 weeks and were followed for 16 weeks total. The primary outcome was the number of heavy drinking days per month (defined as more than 4 drinks per day for men or more than 3 for women). Semaglutide produced approximately a 30% reduction in heavy drinking days compared to placebo (P<0.01). Secondary analyses showed a reduction in total drinks per week and self-reported craving scores on the Penn Alcohol Craving Scale. These results are available in preprint form and have been submitted for peer review as of early 2025; the final published version is pending. ClinicalTrials.gov registration NCT04925544 provides background methodology.

Real-World Observational Data

A large retrospective cohort analysis using TriNetX electronic health records data, published in Nature Communications in 2024, examined patients with both obesity and AUD who were prescribed a GLP-1 receptor agonist versus matched controls. The GLP-1 group showed a statistically significant reduction in AUD-related hospitalizations (hazard ratio 0.64, 95% CI 0.52 to 0.79) over a 12-month observation window. The study was not randomized and cannot establish causation, but the signal size is notable.

A separate analysis of insurance claims data published in JAMA Psychiatry in 2023 found that patients on semaglutide or liraglutide had lower rates of alcohol-related emergency department visits compared to patients on other anti-obesity medications, after adjustment for baseline comorbidities.

Animal and Mechanistic Studies

Preclinical data are the strongest piece of the mechanistic puzzle. A 2022 study in Neuropsychopharmacology showed that once-weekly semaglutide in alcohol-dependent rats reduced ethanol intake by 40 to 60% without significantly affecting food intake at equivalent doses. A 2023 study in Biological Psychiatry demonstrated that semaglutide reduced cue-induced alcohol-seeking behavior in rodents, pointing toward an anti-craving rather than purely aversive mechanism.

What GRADE Says About This Body of Evidence

The GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework, used by major guideline bodies including the WHO and the American College of Physicians, rates evidence quality on four levels: High, Moderate, Low, and Very Low. For semaglutide in AUD, the current rating is GRADE Low for reduction in heavy drinking days and GRADE Very Low for most other outcomes. This means further research is likely to change the estimate of effect. Clinicians and patients should not treat current results as settled science.

What Are the Specific Risks of Using Wegovy Off-Label for AUD?

Gastrointestinal Adverse Effects

Nausea, vomiting, diarrhea, and constipation are the most common adverse effects of semaglutide at any dose. In the STEP-1 trial (N=1,961), nausea occurred in 44% of semaglutide-treated participants versus 16% on placebo, and vomiting in 24% versus 6%. STEP-1 results were published in the NEJM in 2021. In patients with AUD who may already have gastritis, esophageal irritation from chronic alcohol use, or nutritional deficiencies, these GI effects could be more severe or harder to manage.

Pancreatitis Risk

The Wegovy prescribing information carries a warning for acute pancreatitis. Alcohol itself is one of the leading causes of acute pancreatitis, accounting for approximately 30% of cases according to StatPearls via NCBI. Combining a drug with a pancreatitis signal with a condition that independently raises pancreatitis risk is a clinically meaningful concern. Prescribers should assess baseline lipase and amylase and counsel patients to stop the drug immediately if they develop severe upper abdominal pain.

The FDA Suicidality Review

In January 2023, the FDA announced a safety review of GLP-1 receptor agonists including semaglutide for a possible signal of suicidal ideation and self-harm, prompted by reports in the European Medicines Agency's pharmacovigilance database. A subsequent FDA analysis published in 2024 covering over 1.7 million patients found no statistically significant increased risk of suicidality in the general population. However, patients with AUD have baseline rates of suicidal ideation and attempts substantially above the general population. Clinicians should not dismiss this history when prescribing off-label in this group, and structured suicide risk screening (for example, using the Columbia Suicide Severity Rating Scale) is reasonable before initiating.

Thyroid C-Cell Tumor Warning

Wegovy carries a black box warning for thyroid C-cell tumors based on rodent carcinogenicity studies. The FDA label states the drug is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Whether the rodent signal translates to humans remains uncertain; no confirmed cases of semaglutide-induced medullary thyroid carcinoma in humans have been published as of 2025. The warning still applies regardless of indication.

Nutritional Deficiencies in AUD

Patients with moderate-to-severe AUD frequently present with thiamine (B1), folate, B12, magnesium, and zinc deficiencies due to poor dietary intake and impaired absorption. Semaglutide reduces appetite and caloric intake substantially. In the STEP-1 trial, patients lost an average of 15.3 kg over 68 weeks. Adding a potent appetite suppressant in a nutritionally depleted population could worsen micronutrient status without proactive supplementation. Clinicians should check baseline nutritional labs and consider thiamine supplementation prophylactically, following American Society of Addiction Medicine guidelines on withdrawal management.

Drug Interactions

Semaglutide slows gastric emptying, which can alter the absorption of orally administered medications. For AUD patients who may also take naltrexone (oral), acamprosate, or medications for co-occurring psychiatric conditions, this interaction profile deserves attention. A 2022 pharmacokinetic review in Clinical Pharmacokinetics found that semaglutide delayed peak plasma concentration of co-administered oral drugs by a median of 1.5 hours without reducing overall bioavailability in most cases. Clinicians should time critical medications appropriately and monitor for unexpected concentration changes.

FDA-Approved Alternatives for AUD: The Comparison Baseline

Before considering off-label semaglutide, patients and clinicians should confirm whether approved therapies have been adequately tried.

Naltrexone

Naltrexone is a mu-opioid receptor antagonist approved by the FDA in both oral (50 mg daily) and extended-release injectable (380 mg monthly, brand name Vivitrol) formulations. A Cochrane review of 53 randomized trials (N=9,140) concluded that oral naltrexone reduced the return to heavy drinking (risk ratio 0.83, 95% CI 0.76 to 0.91) compared to placebo. That review is available via Cochrane Library. For patients with opioid co-use, naltrexone is contraindicated.

Acamprosate

Acamprosate (333 mg, three times daily) modulates glutamatergic and GABAergic signaling to reduce protracted withdrawal symptoms and craving. A meta-analysis in Addiction (N=6,915) found acamprosate significantly increased the rate of continuous abstinence at 6 months compared to placebo (odds ratio 1.88, 95% CI 1.57 to 2.25). It is renally cleared and dose-adjusted in renal impairment.

Disulfiram

Disulfiram (250 to 500 mg daily) works through aversive conditioning by inhibiting aldehyde dehydrogenase, causing a highly unpleasant reaction to any alcohol ingestion. Adherence is the primary limitation. The NIAAA treatment guidelines list disulfiram as an option primarily for patients with strong motivation and supervised administration.

How Clinicians Are Currently Approaching Off-Label Prescribing

No major medical society, including the American Society of Addiction Medicine, the American Psychiatric Association, or the American College of Gastroenterology, has issued a formal guideline recommending semaglutide for AUD as of mid-2025. Prescribing is therefore driven by individual clinical judgment.

Dr. Lorenzo Leggio, a senior investigator at the National Institute on Alcohol Abuse and Alcoholism and a principal investigator on several GLP-1/AUD trials, has stated publicly that "GLP-1 receptor agonists represent one of the most exciting new directions in addiction medicine, but we need to be cautious about getting ahead of the data." His NIH lab profile and published work are accessible via PubMed.

A clinician considering off-label semaglutide for AUD would typically document:

• Failure of or contraindication to at least one FDA-approved AUD medication
• Comorbid obesity or overweight (BMI ≥27) that would independently support on-label prescribing
• Informed consent explicitly addressing off-label status, evidence limitations, and known risks
• A monitoring plan including LFTs, lipase, nutritional labs, and psychiatric screening at baseline and at 4, 8, and 16 weeks

Active Clinical Trials Patients Can Join

Two trials are actively enrolling as of mid-2025 and offer a pathway for patients to access semaglutide for AUD under research protocols with proper safety monitoring.

NCT04925544 is a phase 2, randomized, double-blind, placebo-controlled trial examining semaglutide in adults with AUD, sponsored by the National Institutes of Health. The registration is accessible on ClinicalTrials.gov via PubMed Central.

NCT05520281 examines the effect of semaglutide on alcohol consumption and craving in heavy drinkers with and without AUD diagnosis, using neuroimaging endpoints to probe the mesolimbic mechanism. Enrollment targets 200 participants at sites in the United States and Denmark.

Patients interested in trial participation should ask their physician for a ClinicalTrials.gov search filtered by "semaglutide" and "alcohol use disorder" with status "Recruiting."

The Risk-Benefit Framework for Individual Patients

The decision to use Wegovy off-label for AUD is not binary. It sits on a spectrum that depends on the individual patient's clinical profile.

Patients who may have a more favorable risk-benefit ratio:

• Adults with comorbid obesity (BMI ≥30) where semaglutide is already on-label, and AUD is an additional treatment target
• Patients who have tried and failed naltrexone and acamprosate
• Patients without personal or family history of medullary thyroid carcinoma or MEN2
• Patients with mild-to-moderate AUD where abstinence is not strictly required and reduction in heavy drinking days is a clinically meaningful goal

Patients where the risks likely outweigh potential benefits:

• Patients with severe AUD requiring medically supervised detoxification, where semaglutide has no evidence of reducing withdrawal seizures or delirium tremens risk
• Patients with a history of pancreatitis
• Patients who are pregnant or planning pregnancy (semaglutide is Category X equivalent; FDA label recommends discontinuing 2 months before planned conception)
• Patients with active suicidal ideation given the unresolved safety signal
• Patients with severe nutritional deficiency who are not yet stabilized on supplementation

The NIAAA defines heavy drinking as more than 4 drinks on any day or more than 14 per week for men, and more than 3 drinks on any day or more than 7 per week for women. Any off-label protocol should use these thresholds to define endpoints and monitor progress.

What Patients Should Ask Their Prescriber

Before agreeing to off-label semaglutide for AUD, patients can protect themselves by asking five specific questions:

1. Have I met the criteria for at least one FDA-approved AUD medication, and if so, why is that not the first choice?
2. Do I also qualify for on-label Wegovy based on my BMI and comorbidities?
3. What lab tests will you order at baseline and during treatment?
4. What are the stopping criteria if I develop side effects?
5. Will you document informed consent including the off-label status in my chart?

A prescriber who cannot answer all five questions clearly may not have adequate familiarity with either the AUD pharmacotherapy literature or the semaglutide safety profile to manage this off-label use responsibly.

Ongoing Research: What the Next 24 Months May Show

The field is moving rapidly. The SELECT cardiovascular outcomes trial (N=17,604) for semaglutide 2.4 mg, published in NEJM in 2023, demonstrated a 20% relative risk reduction in major adverse cardiovascular events over a median 34.2 months. That trial did not specifically enroll patients with AUD, but a subgroup analysis of patients with self-reported alcohol use is anticipated. The NIAAA has committed funding through fiscal year 2026 for GLP-1/AUD clinical trials, suggesting the evidentiary base could improve substantially within 18 to 24 months.

A Cochrane systematic review on GLP-1 receptor agonists for substance use disorders is registered and in protocol phase as of 2025, which will provide the first formal pooled analysis across all available randomized data once completed. Cochrane protocol registrations are searchable via the Cochrane Library.

The phase 3 data needed to move semaglutide from GRADE Low to GRADE High for AUD are not yet published. Until they are, every clinical decision in this space is a judgment call made under meaningful uncertainty.